BOXR-1030 is under clinical development by SOTIO Biotech and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BOXR-1030’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BOXR-1030 overview

BOXR-1030 is under development for the treatment of hepatocellular carcinoma, lung squamous cell carcinoma, myxoid liposarcoma, round cell liposarcoma, merkel cell carcinoma (MCC) and other solid tumors. These comprise T-cells modified to express the antigen-specific receptor (to target cancer cells) and a transgene to modify tumor microenvironment. It act by targeting Glypican 3 (GPC3). The drug candidate is developed based on the Bolt-on chimeric receptor (BOXR) technology. It is administered through intravenous route.

SOTIO Biotech overview

SOTIO Biotech (Sotio), a subsidiary of PPF Group NV, is a biotechnology company that develops immunotherapies for the treatment of cancer. The company is investigating SOT101, a monotherapy in combination with pembrolizumab targeting metastatic solid tumor; and BOXR1030, car-t cell therapy against hepatocellular carcinoma and squamous cell carcinoma. It is also evaluating IL-15, Superagonist based programs to develop immunotherapies in oncology. Sotio utilizes its proprietary BOXR cell therapy platform to design and develop engineered T cells by identifying novel bolt-on transgenes in the solid tumor microenvironment. The company has research laboratories in Prague, Czech Republic; and Cambridge, Massachusetts, the US. Sotio is headquartered in Prague, North Bohemian, Czech Republic.

For a complete picture of BOXR-1030’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.